NASDAQ:HARPHarpoon Therapeutics Stock Price, Forecast & News

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has increased by 4.7% and is now trading at $13.68.
View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Harpoon Therapeutics.

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Harpoon Therapeutics.

Harpoon Therapeutics Inc (NASDAQ:HARP) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.04. Harpoon Therapeutics had a negative return on equity of 62.20% and a negative net margin of 571.20%.
View Harpoon Therapeutics' earnings history.

7 equities research analysts have issued twelve-month price targets for Harpoon Therapeutics' shares. Their forecasts range from $25.00 to $38.00. On average, they anticipate Harpoon Therapeutics' stock price to reach $30.57 in the next year. This suggests a possible upside of 123.5% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics.

News coverage about HARP stock has trended negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Harpoon Therapeutics earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Harpoon Therapeutics.

Harpoon Therapeutics saw a drop in short interest in February. As of February 15th, there was short interest totaling 251,600 shares, a drop of 28.3% from the January 31st total of 351,000 shares. Based on an average daily volume of 141,000 shares, the short-interest ratio is presently 1.8 days. Approximately 1.8% of the company's stock are sold short.
View Harpoon Therapeutics' Short Interest.

Some companies that are related to Harpoon Therapeutics include Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Vaxart (VXRT), Cortexyme (CRTX), Regenxbio (RGNX), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), I-Mab (BDTX), Compugen (CGEN), Alector (ALEC), Translate Bio (TBIO), Adaptimmune Therapeutics (ADAP), Replimune Group (REPL) and Nantkwest (NK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), Gossamer Bio (GOSS), Sorrento Therapeutics (SRNE), Precision BioSciences (DTIL), Inovio Pharmaceuticals (INO), Kaleido Biosciences (KLDO), Tcr2 Therapeutics (TCRR), Homology Medicines (FIXX) and Gilead Sciences (GILD).

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Harpoon Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Bessemer Group Inc. (0.13%), Russell Investments Group Ltd. (0.09%), Virtus ETF Advisers LLC (0.08%), Virtu Financial LLC (0.05%), Strs Ohio (0.05%) and New York State Common Retirement Fund (0.04%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle.
View institutional ownership trends for Harpoon Therapeutics.

HARP stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks, and Patrick Baeuerle.
View insider buying and selling activity for Harpoon Therapeutics.

HARP stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Virtus ETF Advisers LLC, Virtu Financial LLC, Strs Ohio, New York State Common Retirement Fund, and Russell Investments Group Ltd.. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, and Luke Evnin.
View insider buying and selling activity for Harpoon Therapeutics.

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HARP stock can currently be purchased for approximately $13.68.

Harpoon Therapeutics has a market capitalization of $343.94 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.

The official website for Harpoon Therapeutics is www.harpoontx.com.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]